Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Doses First ALS Patients in Phase 2a BANYAN Trial of Intranasal Foralumab

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1
Mkt Cap
$129.592M
52W Low
$0.762
52W High
$2.35
52W Position info
31% above low
Off High info
57% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TLSA sits 31% above its 52-week low of $0.762.

Summary

Tiziana has dosed the first three participants in its Phase 2a BANYAN trial of intranasal foralumab for ALS. The trial will enroll 44 early ALS patients, randomized 3:1 to drug or placebo, with a 12-week treatment period followed by a 12-week extension. Primary endpoint is safety and tolerability; secondary endpoints include Treg induction, gene expression, NfL levels, and microglial activation via TSPO-PET/MRI. This milestone expands foralumab's clinical footprint beyond MS, MSA, and AD into ALS, a high-unmet-need indication. The trial is co-funded by the ALS Association and conducted at Healey & AMG Center and other sites. A community webinar is scheduled for October 1 to discuss the science. This follows recent insider buying by the CEO and Executive Chairman, signaling management confidence. The stock is micro-cap (~$130M), so any positive clinical news can move the price significantly.

Updates

  1. · SEC 6-K — The 6-K attaches the press release announcing the first three participants dosed in the BANYAN trial.

At the time of this announcement, TLSA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $129.6M. The 52-week trading range was $0.76 to $2.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 05, 2026, 2:26 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6249
Real-time Price: $0.670 info
Change: +$0.0451 (+7%) info
Market Cap: $83.144M info
TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.670 info
Change: -$0.220 (-25%) info
Market Cap: $83.144M info
TLSA
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.8685
Real-time Price: $0.670 info
Change: -$0.1985 (-23%) info
Market Cap: $83.144M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.670 info
Change: -$0.380 (-36%) info
Market Cap: $83.144M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.670 info
Change: -$0.400 (-37%) info
Market Cap: $83.144M info